We are live on ! Find out more
SGA

Sector Gamma AS Portfolio holdings

AUM $423M
1-Year Est. Return 17.56%
This Fund
S&P 500
This Quarter Est. Return
+1.62%
1 Year Est. Return
+17.56%
3 Year Est. Return
+28.73%
5 Year Est. Return
+52.48%
10 Year Est. Return
+238.19%
AUM
$656M
AUM Growth
-$31.7M
Cap. Flow
-$44.4M
Cap. Flow %
-6.77%
Top 10 Hldgs %
63.24%
Holding
31
New
5
Increased
8
Reduced
14
Closed
3

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$23.4M
2
LLY icon
Eli Lilly
LLY
+$20M
3
NUVA
NuVasive, Inc.
NUVA
+$12.1M
4
CLVS
Clovis Oncology, Inc.
CLVS
+$11.7M
5
BIIB icon
Biogen
BIIB
+$7.76M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$25.1M
2
MASI
Masimo
MASI
+$18.4M
3
GILD icon
Gilead Sciences
GILD
+$16.3M
4
ABT icon
Abbott
ABT
+$13.3M
5
LPNT
LifePoint Health, Inc.
LPNT
+$10.1M

Sector Composition

Rank Sector Weight
1 Healthcare 98.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABT icon
1
Abbott
ABT
$175B
$67.9M 10.34%
1,271,742
-265,600
-17% -$13.3M
LLY icon
2
Eli Lilly
LLY
$1.05T
$61.5M 9.38%
719,546
+244,296
+51% +$20M
BAX icon
3
Baxter International
BAX
$11.7B
$58.6M 8.93%
934,133
-136,200
-13% -$8.41M
BSX icon
4
Boston Scientific
BSX
$65.4B
$42.8M 6.53%
1,468,880
+31,400
+2% +$867K
RVTY icon
5
Revvity
RVTY
$12.3B
$37.4M 5.69%
541,608
-89,700
-14% -$6.02M
ELV icon
6
Elevance Health
ELV
$80.9B
$34.7M 5.29%
182,610
+3,200
+2% +$609K
BMY icon
7
Bristol-Myers Squibb
BMY
$124B
$29.3M 4.47%
459,606
-429,784
-48% -$25.1M
IRWD icon
8
Ironwood Pharmaceuticals
IRWD
$635M
$28.8M 4.39%
2,179,052
-9,666
-0.4% -$133K
GILD icon
9
Gilead Sciences
GILD
$167B
$27.2M 4.15%
335,690
-212,700
-39% -$16.3M
IART icon
10
Integra LifeSciences
IART
$1.5B
$26.7M 4.07%
529,230
+36,000
+7% +$1.85M
BIIB icon
11
Biogen
BIIB
$30.4B
$26.3M 4.01%
84,000
+26,200
+45% +$7.76M
AZN icon
12
AstraZeneca
AZN
$262B
$25.1M 3.82%
+370,336
New +$23.4M
SHPG
13
DELISTED
Shire pic
SHPG
$24.8M 3.79%
162,156
-45,705
-22% -$7.16M
BIO icon
14
Bio-Rad Laboratories Class A
BIO
$8.15B
$24.3M 3.71%
109,440
-5,502
-5% -$1.24M
PRGO icon
15
Perrigo
PRGO
$1.48B
$23.7M 3.61%
279,440
-13,700
-5% -$1.07M
MCK icon
16
McKesson
MCK
$98.5B
$18.3M 2.79%
119,100
+3,000
+3% +$468K
PDCO
17
DELISTED
Patterson Companies, Inc.
PDCO
$15.3M 2.33%
396,332
+10,100
+3% +$403K
CLVS
18
DELISTED
Clovis Oncology, Inc.
CLVS
$12.2M 1.86%
+148,092
New +$11.7M
LH icon
19
Labcorp
LH
$23.2B
$10.6M 1.61%
81,480
-17,460
-18% -$2.33M
NUVA
20
DELISTED
NuVasive, Inc.
NUVA
$10.1M 1.55%
+183,000
New +$12.1M
LXRX icon
21
Lexicon Pharmaceuticals
LXRX
$1.06B
$9.06M 1.38%
737,453
+114,798
+18% +$1.7M
IPXL
22
DELISTED
Impax Laboratories, Inc.
IPXL
$8.57M 1.31%
422,261
-167,050
-28% -$3.19M
THC icon
23
Tenet Healthcare
THC
$16.8B
$8.46M 1.29%
515,180
-60,000
-10% -$1.02M
CI icon
24
Cigna
CI
$74.5B
$6.24M 0.95%
33,370
-50,900
-60% -$9.06M
MNTA
25
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$5.92M 0.9%
320,055
-285,490
-47% -$4.77M
1
2

Similar funds

AFWM
AMJ Financial Wealth Management Leesburg, Virginia $424M AUM 37.24% 1-Year Est. Return
MP
McDonald Partners Cleveland, Ohio $424M AUM 29.07% 1-Year Est. Return
DS
Dalal Street West Lake Hills, Texas $423M AUM 115.19% 1-Year Est. Return
RS
Retirement Solution Redmond, Washington $423M AUM 16.83% 1-Year Est. Return
DF
Dunhill Financial London, United Kingdom $424M AUM 16.79% 1-Year Est. Return
OGM
OnyxPoint Global Management New York $424M AUM 84.95% 1-Year Est. Return
CPIM
Cypress Point Investment Management Mill Valley, California $424M AUM
MPPLM
Midwest Professional Planners Ltd (MPPL) Wausau, Wisconsin $425M AUM 28.89% 1-Year Est. Return

Sector Gamma AS's Q3 2017 Portfolio in Review

As of Q3 2017, Sector Gamma AS held 31 positions worth $656M, down 4.6% from $688M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Sector Gamma AS withdrew a net $44.4M in Q3 2017, closing 3 positions and reducing 14 holdings. Its most notable exit was Masimo, an estimated $18.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier.

Against the trend, Sector Gamma AS opened a new position in AstraZeneca worth $25.1M.

  • Sector Gamma AS's largest Q3 2017 buy was AstraZeneca: 370,336 shares worth $25.1M.
  • Sector Gamma AS added most to Eli Lilly in Q3 2017, an estimated $20M increase.
  • Sector Gamma AS's biggest Q3 2017 reduction was Bristol-Myers Squibb, cutting an estimated $25.1M.
  • Sector Gamma AS fully exited Masimo in Q3 2017, selling an estimated $18.4M.
  • Sector Gamma AS's ten largest holdings make up 63% of its $656M portfolio in Q3 2017.
  • Sector Gamma AS opened 5 new positions and closed 3 in Q3 2017.
  • Sector Gamma AS's portfolio value fell 4.6% quarter-over-quarter to $656M.

Based on Sector Gamma AS's 13F filing for Q3 2017, filed 7 Nov 2017.